Insider · CIK 0001654337

Ali-Jackson Kamil

Reports to the SEC for 3 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001654337

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-22	RIGLRIGEL PHARMACEUTICALS INCS Sale	Director	SSale	−2,500 sh	$35.00	−$87.5K	10,125
2026-05-26	RIGLRIGEL PHARMACEUTICALS INCS Sale	Director	SSale	−2,500 sh	$29.17	−$72.9K	12,625
2026-05-15	RIGLRIGEL PHARMACEUTICALS INCA Award	Director	AAward	+5,750 sh	—	—	15,125
2026-01-12	PDSBPDS Biotechnology Corp · Employee Stock Option (Right to Buy)A Award	Director	AAward	+54.9K sh	—	—	54,876
2025-06-11	PDSBPDS Biotechnology Corp · Employee Stock Option (Right to Buy)A Award	Director	AAward	+22.7K sh	—	—	22,700
2025-05-23	RIGLRIGEL PHARMACEUTICALS INCA Award	Director	AAward	+2,500 sh	—	—	9,375
2025-05-23	RIGLRIGEL PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+3,000 sh	—	—	3,000
2024-06-24	PDSBPDS Biotechnology Corp · Employee Stock Option (Right to Buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2024-05-25	RIGLRIGEL PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2024-05-25	RIGLRIGEL PHARMACEUTICALS INCA Award	Director	AAward	+25K sh	—	—	68,750
2023-07-14	PDSBPDS Biotechnology Corp · Employee Stock Option (Right to Buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2023-05-26	RIGLRIGEL PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-05-26	RIGLRIGEL PHARMACEUTICALS INCA Award	Director	AAward	+25K sh	—	—	43,750
2022-06-28	PDSBPDS Biotechnology Corp · Stock Option (Right to Buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2022-05-20	RIGLRIGEL PHARMACEUTICALS INCA Award	Director	AAward	+18.8K sh	—	—	18,750
2022-05-20	RIGLRIGEL PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2022-01-03	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+27.9K sh	—	—	146,476
2022-01-03	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+3,875 sh	—	—	118,571
2022-01-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−7,100 sh	—	—	0
2022-01-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−3,875 sh	—	—	0
2022-01-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−6,638 sh	—	—	0
2022-01-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−27.9K sh	—	—	0
2022-01-03	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+7,100 sh	—	—	160,214
2022-01-03	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+6,638 sh	—	—	153,114
2021-12-16	RIGLRIGEL PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+120K sh	—	—	120,000
2021-06-17	PDSBPDS Biotechnology Corp · Stock Option (Right to Buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2021-06-15	PDSBPDS Biotechnology CorpP Purchase	Director	PPurchase	+11.8K sh	$8.50	+$100K	11,764
2021-06-03	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−9,492 sh	$21.96	−$208K	122,196
2021-06-02	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−2,387 sh	$22.31	−$53.3K	131,688
2021-06-02	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−2,517 sh	$22.32	−$56.2K	146,807
2021-06-02	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−12.7K sh	$21.51	−$274K	134,075
2021-06-02	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−12.5K sh	$21.50	−$268K	149,324
2021-06-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+33.2K sh	—	—	176,807
2021-06-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−33.2K sh	—	—	0
2021-06-01	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−9,746 sh	$22.72	−$221K	167,061
2021-06-01	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−5,254 sh	$23.57	−$124K	161,807
2021-05-07	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−5,416 sh	—	—	0
2021-05-07	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−3,316 sh	$23.23	−$77K	145,718
2021-05-07	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−2,100 sh	$23.99	−$50.4K	143,618
2021-05-07	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+5,416 sh	$10.66	+$57.7K	149,034
2021-05-06	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−15K sh	—	—	5,416
2021-05-06	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−11.9K sh	$23.32	−$277K	146,720
2021-05-06	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−3,102 sh	$23.86	−$74K	143,618
2021-05-06	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+15K sh	$10.66	+$160K	158,618
2021-05-05	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−14.5K sh	$23.97	−$348K	144,116
2021-05-05	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−498 sh	$24.36	−$12.1K	143,618
2021-05-05	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	−15K sh	—	—	20,416
2021-05-05	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+15K sh	$10.66	+$160K	158,618
2021-05-04	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer	MExercise/Conversion	+15K sh	$10.66	+$160K	158,618
2021-05-04	ACRSAclaris Therapeutics, Inc.S Sale	Chief Legal Officer	SSale	−13.7K sh	$23.61	−$324K	144,897

Recent filings

Accepted (ET)
Jun 244
Ali-Jackson Kamil0000905148-26-003076
SEC(opens sec.gov)
May 284
Ali-Jackson Kamil0000905148-26-002724
SEC(opens sec.gov)
May 194
Ali-Jackson Kamil0000905148-26-002529
SEC(opens sec.gov)
Mar 34
Ali-Jackson Kamil0001140361-26-007641
SEC(opens sec.gov)
Jun 114
Ali-Jackson Kamil0001140361-25-022225
SEC(opens sec.gov)
May 284
Ali-Jackson Kamil0000905148-25-001935
SEC(opens sec.gov)
Jun 254
Ali-Jackson Kamil0001140361-24-031289
SEC(opens sec.gov)
May 294
Ali-Jackson Kamil0000905148-24-001651
SEC(opens sec.gov)
Jul 174
Ali-Jackson Kamil0001140361-23-034836
SEC(opens sec.gov)
Jul 124
Ali-Jackson Kamil0001140361-23-034284
SEC(opens sec.gov)
Jun 294
Ali-Jackson Kamil0001140361-22-024466
SEC(opens sec.gov)
May 234
Ali-Jackson Kamil0001140361-22-020303
SEC(opens sec.gov)
Jan 54
Ali-Jackson Kamil0001209191-22-001712
SEC(opens sec.gov)

Companies

Address

RIGEL PHARMACEUTICALS, INC. 611 GATEWAY BLVD, SUITE 900

SOUTH SAN FRANCISCO, CA, 94080